載入...
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-pati...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Libertas Academica
2012
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3619699/ https://ncbi.nlm.nih.gov/pubmed/23650473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/JCNSD.S9107 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|